Scientific intelligence record
Experience 2.0
Amylin analog
Cagrilintide is an amylin analog investigated for weight management, both alone and in combinations such as CagriSema. Evidence for the single agent must be separated from evidence for the combination.
Record status
Traceability partial
Last meaningful update: 9/23/2026
Ranked research corpus
118
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
Investigational boundary: Cagrilintide is not presented here as FDA-approved, and screening records must not be interpreted as established clinical benefit.
118 matching records · ranked 2026-09-18
Page 1 of 5
BMJ medicine · 2026 · PMID 42688617 · DOI 10.1136/bmjmed-2026-003026
Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness
The American journal of cardiology · 2026 May 15 · PMID 41759565 · DOI 10.1016/j.amjcard.2026.02.030
Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Comparative effectiveness
Diabetes, obesity & metabolism · 2026 Jun · PMID 41834765 · DOI 10.1111/dom.70667
Weight loss and obesity · CagriSema combination evidence · Safety and tolerability · Comparative effectiveness
Endocrinology, diabetes & metabolism · 2026 May · PMID 42175595 · DOI 10.1002/edm2.70247
Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Comparative effectiveness
Annals of medicine and surgery (2012) · 2026 Aug · PMID 42583410 · DOI 10.1097/MS9.0000000000005353
Weight loss and obesity · Amylin biology · CagriSema combination evidence · Comparative effectiveness
Journal of diabetes and metabolic disorders · 2026 Jun · PMID 42180166 · DOI 10.1007/s40200-026-01942-3
Weight loss and obesity · CagriSema combination evidence · Safety and tolerability
Endocrinology, diabetes & metabolism · 2026 Jul · PMID 42207966 · DOI 10.1002/edm2.70248
Weight loss and obesity · CagriSema combination evidence · Comparative effectiveness
Annals of internal medicine · 2026 Aug · PMID 42296503 · DOI 10.7326/ANNALS-24-03764
Weight loss and obesity · Mechanism and pharmacology · Comparative effectiveness
BMJ (Clinical research ed.) · 2024 Jan 29 · PMID 38286487 · DOI 10.1136/bmj-2023-076410
Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Mechanism and pharmacology · Comparative effectiveness
Obesity (Silver Spring, Md.) · 2026 Sep · PMID 41189318 · DOI 10.1002/oby.70054
Weight loss and obesity · Safety and tolerability
BMJ (Clinical research ed.) · 2026 Jul 8 · PMID 42419792 · DOI 10.1136/bmj-2026-372161
Weight loss and obesity · Comparative effectiveness
Naunyn-Schmiedeberg's archives of pharmacology · 2026 Aug 17 · PMID 42608559 · DOI 10.1007/s00210-026-05809-5
Weight loss and obesity · CagriSema combination evidence
Indian journal of endocrinology and metabolism · 2024 Sep-Oct · PMID 39676787 · DOI 10.4103/ijem.ijem_45_24
Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Safety and tolerability
Annals of internal medicine · 2026 Sep 1 · PMID 42673585 · DOI 10.7326/ANNALS-25-05519
Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024 Feb · PMID 38242040 · DOI 10.1016/j.biopha.2024.116150
Weight loss and obesity · Safety and tolerability · Comparative effectiveness
The lancet. Diabetes & endocrinology · 2026 Jun · PMID 42009015 · DOI 10.1016/S2213-8587(25)00402-4
Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness · Ongoing development
BMJ open · 2025 Sep 21 · PMID 40976663 · DOI 10.1136/bmjopen-2025-103668
Ongoing development
The lancet. Diabetes & endocrinology · 2026 Aug · PMID 42251859 · DOI 10.1016/S2213-8587(26)00125-7
CagriSema combination evidence · Type 2 diabetes and glycemia · Comparative effectiveness · Ongoing development
The lancet. Diabetes & endocrinology · 2026 Aug · PMID 42251860 · DOI 10.1016/S2213-8587(26)00126-9
CagriSema combination evidence · Type 2 diabetes and glycemia · Safety and tolerability · Ongoing development
Lancet (London, England) · 2026 Jul 4 · PMID 42251856 · DOI 10.1016/S0140-6736(26)01022-6
CagriSema combination evidence · Type 2 diabetes and glycemia · Ongoing development
Cureus · 2025 Mar · PMID 40206909 · DOI 10.7759/cureus.80321
Weight loss and obesity · CagriSema combination evidence
Hypertension (Dallas, Tex. : 1979) · 2026 Feb · PMID 41328546 · DOI 10.1161/HYPERTENSIONAHA.125.26055
Weight loss and obesity · CagriSema combination evidence
Clinical pharmacokinetics · 2026 Jul · PMID 42228334 · DOI 10.1007/s40262-026-01654-0
Safety and tolerability · Mechanism and pharmacology
The lancet. Gastroenterology & hepatology · 2026 Sep · PMID 42456707 · DOI 10.1016/S2468-1253(26)00123-8
CagriSema combination evidence · Safety and tolerability
Expert opinion on investigational drugs · 2025 Mar · PMID 40022548 · DOI 10.1080/13543784.2025.2472408
Weight loss and obesity · Amylin biology · Mechanism and pharmacology
Cagrilintide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). Cagrilintide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 23, 2026.) https://www.worldpeptidefoundation.org/directory/cagrilintide
AMA / Vancouver
World Peptide Foundation. Cagrilintide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 23, 2026. https://www.worldpeptidefoundation.org/directory/cagrilintide
Featured tiered studies
36
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
12
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
26
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
118
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
36
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
12
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
26
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Cagrilintide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasContent-verified record concerning Cagrilintide: "Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study." Abstract excerpt: Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia. We aimed to compare the efficacy and safety of a once per week combination of cagrilintide with semaglutide (CagriSema) versus placebo as an add-on to basal insulin in individuals with type 2 diabetes. This double-blind, parallel-group, r
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2021 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
systematic_review_or_meta_analysis
2024 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
systematic_review_or_meta_analysis
2026 · regulatory · Temporal status not established
European Union — EMA
2026 · regulatory · Temporal status not established
United States — FDA
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 12 domain conclusions and 36 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Cagrilintide evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union — EMA
Regulator: EMA
As of: 9/23/2026 · Temporal status not established
United States — FDA
Regulator: FDA
As of: 9/23/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 4:01:37 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
Content-verified record concerning Cagrilintide: "Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study." Abstract excerpt: The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight. We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overw
Content-verified record concerning Cagrilintide: "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial." Abstract excerpt: Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We assessed the dose-response relationship of cagrilintide regarding the effects on bodyweight, safety, and tolerability. We conducted a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial at 57
Content-verified record concerning Cagrilintide: "Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial." Abstract excerpt: The combination of cagrilintide and semaglutide has been shown in global studies to induce reductions in bodyweight. We assessed the efficacy and safety of a fixed-dose combination of cagrilintide 2·4 mg and semaglutide 2·4 mg versus semaglutide 2·4 mg for weight management in an east Asian population. This double-blind, parallel-group, phase 3a trial (REDEFINE 5) was conducted acro
Content-verified record concerning Cagrilintide: "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial." Abstract excerpt: Cagrilintide, a long-acting amylin analogue, and semaglutide 2·4 mg, a glucagon-like peptide-1 analogue, are both being investigated as options for weight management. We aimed to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of this drug combination. In this randomised, placebo-controlled, multiple-ascending dose, phase 1b trial, individuals aged 18-55 years with
Content-verified record concerning Cagrilintide: "Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." Abstract excerpt: Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. We aimed to assess the efficacy and safety of cagrilintide-semaglutide for people with type 2 diabetes inadequately controlled with diet and exercise. REIMAGINE 1 was a randomised, double-blind, parallel-group, phase 3a study carried out a
Content-verified record concerning Cagrilintide: "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial." Abstract excerpt: Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA 1c ) is unknown. This trial assessed the efficacy and safety of co-administered semaglutide with cagrilintide (CagriSema) in participants with type 2 diabetes. This 32-week, multicentre, double-blind, phase 2 trial was conducted across
Directly concerns the combination in adults with overweight or obesity; does not isolate cagrilintide alone.
Content-verified record concerning Cagrilintide: "Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats." Abstract excerpt: Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes. Here we demonstrate enhanced metabolic benefits of a combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GCGR tri-agonist, and cagrilintide, an AMLNR/CALCR co-agonist, in diet-induced obe
Content-verified record concerning Cagrilintide: "In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk." Abstract excerpt: GIM/FP/GP: [Formula: see text].
Content-verified record concerning Cagrilintide: "Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes." Abstract excerpt: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12
Content-verified record concerning Cagrilintide: "A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance." Abstract excerpt: Amylin receptor agonists such as cagrilintide represent emerging obesity therapies. To understand mediators of cagrilintide action, we generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling to map distribution in the rat dorsal vagal complex (DVC). Here we show that cagrilintide regulate
Content-verified record concerning Cagrilintide: "Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models." Abstract excerpt: Cagrilintide is a novel long-acting amylin receptor agonist, which has shown a potent induction of weight loss. Interestingly, cagrilintide is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) derived from an amylin backbone. Another class of long-acting DACRAs exists, namely the KBPs. These are salmon calcitonin-based and have shown preclinical potential; however, how and if they differentiat
Content-verified record concerning Cagrilintide: "Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide." Abstract excerpt: Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for mouse and rat in vivo and in vitro studies of amylin analogues such as cagrilintide. Structurally, 0839 shares 95 % sequence homology with 0833 a
Content-verified record concerning Cagrilintide: "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity." Abstract excerpt: Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the
Content-verified record concerning Cagrilintide: "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." Abstract excerpt: No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, l
Content-verified record concerning Cagrilintide: "Cagrilintide-semaglutide: a new option for patients with type 2 diabetes." (identity confirmed; no abstract text available to excerpt.)
Content-verified record concerning Cagrilintide: "Cagrilintide plus semaglutide for obesity management." (identity confirmed; no abstract text available to excerpt.)
Content-verified record concerning Cagrilintide: "Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo." Abstract excerpt: Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches. This systematic review and meta-analysis evaluated their efficacy and safety in adults with overweight or obesity. Four databases were searched from i
Content-verified record concerning Cagrilintide: "Cellular loci for cagrilintide action identified." (identity confirmed; no abstract text available to excerpt.)
Content-verified record concerning Cagrilintide: "Development of Cagrilintide, a Long-Acting Amylin Analogue." Abstract excerpt: A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life. We report here the development of the stable, lipidated long-acti
Content-verified record concerning Cagrilintide: "Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide." Abstract excerpt: Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes. Two studies were conducted to assess the effects of renal or hepatic impairment on pharmacokinetics, safety and tolerability following sin
Content-verified record concerning Cagrilintide: "Cagrilintide-Semaglutide in Adults with Overweight or Obesity." (identity confirmed; no abstract text available to excerpt.)
Content-verified record concerning Cagrilintide: "Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis." Abstract excerpt: Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of cagrilintide-based therapies in adults with overwe
Content-verified record concerning Cagrilintide: "Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression." Abstract excerpt: Obesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity. We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintid
Content-verified record concerning Cagrilintide: "Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants." Abstract excerpt: The combination of cagrilintide and semaglutide (CagriSema) is being developed for the treatment of obesity and type 2 diabetes. The objective of this thorough QT study was to confirm that cagrilintide does not result in a clinically relevant prolongation in cardiac repolarization compared with placebo. This was a double-blind study (NCT05804162) in which healthy participants were randomized to ca